Psilocin Co-Crystal Formulation for Stability and Dissolution Control

The patent changes the physical and chemical parameters of psilocin by forming co-crystals with specific co-formers (L-lactic acid, decanoic acid, ethyl maltol, oleic acid, palmitic acid, p-coumaric acid, propyl gallate, and stearic acid). This transforms the solid form from amorphous or poorly crystalline to highly crystalline, thereby improving chemical and physical stability while also enhancing processability for pharmaceutical manufacturing.

The patent creates composite crystalline structures by combining psilocin with multiple different co-formers to produce co-crystals. Each co-crystal combination represents a composite material with optimized properties, where the co-former molecules are incorporated into the crystal lattice with psilocin, resulting in enhanced stability and improved manufacturing characteristics.

The patent segments the co-former options into distinct categories (L-lactic acid, decanoic acid, ethyl maltol, oleic acid, palmitic acid, p-coumaric acid, propyl gallate, and stearic acid), allowing systematic evaluation and selection of the most suitable co-former(s). This segmentation enables managed complexity by organizing the development process into manageable steps rather than treating all possibilities as a single complex problem.

By systematically varying the chemical structure and properties of co-formers (changing parameters such as molecular size, functional groups, and physical properties), the patent optimizes crystallinity and stability while managing development complexity through structured parameter exploration rather than unstructured trial-and-error.

The patent modulates dissolution rate and solubility by changing the crystal structure parameters through co-crystal formation. Different co-formers produce co-crystals with different lattice energies, packing arrangements, and surface properties, which systematically control dissolution characteristics. This provides predictable control over dissolution behavior rather than unpredictable variation.

The co-formers act as intermediary substances that mediate between psilocin molecules, facilitating the formation of crystal structures with optimized dissolution properties. These co-formers serve as control elements that allow pharmacologists to tune dissolution characteristics by selecting appropriate co-formers, making the control process more manageable and predictable.